Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

Cell Research

Volumn 27, Issue 1, 2017, Pages 151-153

  Liu, Kefang ^a,b   Tan, Shuguang ^c   Chai, Yan ^c   Chen, Danqing ^c   Song, Hao ^d   Zhang, Catherine Wei Hong ^e   Shi, Yi ^c   Liu, Jun ^a,b   Tan, Wenjie ^a,b   Lyu, Jianxin ^a   Gao, Shan ^f   Yan, Jinghua ^c   Qi, Jianxun ^c   Gao, George F ^a,b,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c INSTITUTE OF MICROBIOLOGY   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^e ImmuFucell Biotechnology Co Ltd   (China)

^f SUZHOU INSTITUTE OF BIOMEDICAL ENGINEERING AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AVELUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL; BINDING COMPETITION; CHEMISTRY; HUMAN; MOLECULAR MODEL; MOUSE; NEOPLASM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; BINDING, COMPETITIVE; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84984856715     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2016.102     Document Type: Letter

References (10)

1. Powles T, Eder JP, Fine GD, et al. Nature 2014; 515:558.
2. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Lancet 2016; 387:1909-1920.
3. Tan S, Gao GF. Chinese Sci Bull 2015; 60:3155-3157. (In Chinese)
4. Callahan MK, Postow MA, Wolchok JD. Immunity 2016; 44:1069-1078.
5. Na Z, Yeo SP, Bharath SR, et al. Cell Res 2017; 27:147-150.
6. Madan RA, Donahue RN, Singh H, et al. J Clin Oncol 2016; 34(suppl 2S):a214.
7. Chen Y, Liu P, Gao F, et al. Protein Cell 2010; 1:153-160.
8. Lin DY, Tanaka Y, Iwasaki M, et al. Proc Natl Acad Sci USA 2008; 105:3011-3016.
9. Zak KM, Kitel R, Przetocka S, et al. Structure 2015; 23:2341-2348.
10. Maute RL, Gordon SR, Mayer AT, et al. Proc Natl Acad Sci USA 2015; 112:E6506-E6514.